Beam Therapeutics (BEAM) Stock Forecast & Price Target

Compare

2,152 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BEAM Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Beam

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BEAM Stock 12 Month Forecast

Average Price Target

$48.56

▲(80.19% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $48.56 with a high forecast of $80.00 and a low forecast of $28.00. The average price target represents a 80.19% change from the last price of $26.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","48":"$48","81":"$81","31.5":"$31.5","64.5":"$64.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,31.5,48,64.5,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.92,31.92615384615385,35.932307692307695,39.93846153846154,43.94461538461539,47.95076923076923,51.956923076923076,55.963076923076926,59.96923076923077,63.97538461538461,67.98153846153846,71.9876923076923,75.99384615384615,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.92,29.50769230769231,31.095384615384617,32.683076923076925,34.27076923076923,35.85846153846154,37.44615384615385,39.033846153846156,40.621538461538464,42.20923076923077,43.79692307692308,45.38461538461539,46.972307692307695,{"y":48.56,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.92,27.92615384615385,27.932307692307695,27.93846153846154,27.944615384615386,27.950769230769232,27.95692307692308,27.963076923076922,27.96923076923077,27.975384615384616,27.981538461538463,27.987692307692306,27.993846153846153,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.34,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.83,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.31,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.72,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.92,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$80.00

Average Price Target$48.56

Lowest Price Target$28.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sami Corwin

William Blair

Buy

―

Reiterated

02/02/26

Analysts Are Bullish on Top Healthcare Stocks: Spectral AI (MDAI), Schrodinger (SDGR)

Soumit Roy

JonesTrading

$35

Buy

29.87%

Upside

Assigned

01/23/26

JonesTrading Sticks to Its Buy Rating for Beam Therapeutics (BEAM)

Brian Cheng

J.P. Morgan

$46

Buy

70.69%

Upside

Reiterated

01/21/26

Beam Therapeutics: Undervalued Base-Editing Leader with De-Risked BEAM-302 Driving $46 Price Target and Overweight/Buy Rating

William Pickering

Bernstein

$37→$41

Buy

52.13%

Upside

Reiterated

01/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: TransMedics Group (NASDAQ: TMDX), Beam Therapeutics (NASDAQ: BEAM) and Boston Scientific (NYSE: BSX)

Patrick Trucchio

H.C. Wainwright

$80

Buy

196.85%

Upside

Reiterated

01/14/26

Beam Therapeutics: De-Risked Late-Stage Pipeline, Clear FDA Pathways, and Strong Cash Runway Underscore Buy Rating and $80 Target

Cory Kasimov

Evercore ISI

$35

Buy

29.87%

Upside

Reiterated

01/14/26

Evercore ISI Remains a Buy on Beam Therapeutics (BEAM)

Alec Stranahan

Bank of America Securities

$45

Buy

66.98%

Upside

Reiterated

01/14/26

Beam Therapeutics (BEAM) Receives a Buy from Bank of America Securities

Michael Yee

UBS

$28

Hold

3.90%

Upside

Initiated

01/06/26

Beam Therapeutics initiated with a Neutral at UBSBeam Therapeutics initiated with a Neutral at UBS

Yanan Zhu

Wells Fargo

$100→$70

Buy

159.74%

Upside

Reiterated

01/05/26

Wells Fargo Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

David Nierengarten

Wedbush

$57

Buy

111.50%

Upside

Reiterated

12/09/25

Beam Therapeutics (BEAM) Receives a Buy from Wedbush

Gena Wang

Barclays

$21

Hold

-22.08%

Downside

Reiterated

11/05/25

Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)

William Maughan

Clear Street

$34→$37

Buy

37.29%

Upside

Reiterated

11/04/25

Beam Therapeutics price target raised to $37 from $34 at Clear StreetBeam Therapeutics price target raised to $37 from $34 at Clear Street

Luca Issi

RBC Capital

$22

Hold

-18.37%

Downside

Reiterated

11/04/25

RBC Capital Sticks to Their Hold Rating for Beam Therapeutics (BEAM)

Maury Raycroft

Jefferies

$41

Buy

52.13%

Upside

Initiated

10/09/25

Beam Therapeutics initiated with a Buy at JefferiesBeam Therapeutics initiated with a Buy at Jefferies

Mani Foroohar

Leerink Partners

Buy

―

Reiterated

09/03/25

We continue to see the risk/reward skewed favorably into updated data early-26.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sami Corwin

William Blair

Buy

―

Reiterated

02/02/26

Analysts Are Bullish on Top Healthcare Stocks: Spectral AI (MDAI), Schrodinger (SDGR)

Soumit Roy

JonesTrading

$35

Buy

29.87%

Upside

Assigned

01/23/26

JonesTrading Sticks to Its Buy Rating for Beam Therapeutics (BEAM)

Brian Cheng

J.P. Morgan

$46

Buy

70.69%

Upside

Reiterated

01/21/26

Beam Therapeutics: Undervalued Base-Editing Leader with De-Risked BEAM-302 Driving $46 Price Target and Overweight/Buy Rating

William Pickering

Bernstein

$37→$41

Buy

52.13%

Upside

Reiterated

01/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: TransMedics Group (NASDAQ: TMDX), Beam Therapeutics (NASDAQ: BEAM) and Boston Scientific (NYSE: BSX)

Patrick Trucchio

H.C. Wainwright

$80

Buy

196.85%

Upside

Reiterated

01/14/26

Beam Therapeutics: De-Risked Late-Stage Pipeline, Clear FDA Pathways, and Strong Cash Runway Underscore Buy Rating and $80 Target

Cory Kasimov

Evercore ISI

$35

Buy

29.87%

Upside

Reiterated

01/14/26

Evercore ISI Remains a Buy on Beam Therapeutics (BEAM)

Alec Stranahan

Bank of America Securities

$45

Buy

66.98%

Upside

Reiterated

01/14/26

Beam Therapeutics (BEAM) Receives a Buy from Bank of America Securities

Michael Yee

UBS

$28

Hold

3.90%

Upside

Initiated

01/06/26

Beam Therapeutics initiated with a Neutral at UBSBeam Therapeutics initiated with a Neutral at UBS

Yanan Zhu

Wells Fargo

$100→$70

Buy

159.74%

Upside

Reiterated

01/05/26

Wells Fargo Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

David Nierengarten

Wedbush

$57

Buy

111.50%

Upside

Reiterated

12/09/25

Beam Therapeutics (BEAM) Receives a Buy from Wedbush

Gena Wang

Barclays

$21

Hold

-22.08%

Downside

Reiterated

11/05/25

Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)

William Maughan

Clear Street

$34→$37

Buy

37.29%

Upside

Reiterated

11/04/25

Beam Therapeutics price target raised to $37 from $34 at Clear StreetBeam Therapeutics price target raised to $37 from $34 at Clear Street

Luca Issi

RBC Capital

$22

Hold

-18.37%

Downside

Reiterated

11/04/25

RBC Capital Sticks to Their Hold Rating for Beam Therapeutics (BEAM)

Maury Raycroft

Jefferies

$41

Buy

52.13%

Upside

Initiated

10/09/25

Beam Therapeutics initiated with a Buy at JefferiesBeam Therapeutics initiated with a Buy at Jefferies

Mani Foroohar

Leerink Partners

Buy

―

Reiterated

09/03/25

We continue to see the risk/reward skewed favorably into updated data early-26.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Beam Therapeutics

3 Months

xxx

Success Rate

12/15 ratings generated profit

Average Return

+9.57%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +9.57% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

11/15 ratings generated profit

Average Return

+43.51%

reiterated a buy rating 23 days ago

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +43.51% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+55.05%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +55.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BEAM Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BEAM has received 21 Buy Ratings, 30 Hold Ratings, and 0 Sell Ratings. BEAM average Analyst price target in the past 3 months is 48.56.

Each month's total comprises the sum of three months' worth of ratings.

BEAM Financial Forecast

BEAM Earnings Forecast

Next quarter’s earnings estimate for BEAM is -$1.00 with a range of -$1.28 to $1.12. The previous quarter’s EPS was -$1.10. BEAM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.

BEAM Sales Forecast

Next quarter’s sales forecast for BEAM is $11.80M with a range of $0.00 to $25.00M. The previous quarter’s sales results were $9.70M. BEAM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.

BEAM Stock Forecast FAQ

What is BEAM’s average 12-month price target, according to analysts?

Based on analyst ratings, Beam Therapeutics’s 12-month average price target is 48.56.

What is BEAM’s upside potential, based on the analysts’ average price target?

Beam Therapeutics has 80.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BEAM a Buy, Sell or Hold?

Beam Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Beam Therapeutics’s price target?

The average price target for Beam Therapeutics is 48.56. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $28.00. The average price target represents 80.19% Increase from the current price of $26.95.

What do analysts say about Beam Therapeutics?

Beam Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of BEAM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Beam Therapeutics (BEAM) Stock Forecast & Price Target

BEAM Analyst Ratings

BEAM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Beam Therapeutics

BEAM Analyst Recommendation Trends

BEAM Financial Forecast

BEAM Earnings Forecast

BEAM Sales Forecast

BEAM Stock Forecast FAQ

Detailed List of Analyst Forecasts